查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1588404

无菌注射契约製造的市场规模、份额和趋势分析报告：按分子类型、给药途径、治疗用途、最终用途、地区和细分市场进行预测，2025-2030

Sterile Injectable Contract Manufacturing Market Size, Share & Trends Analysis Report Molecule Type (Small Molecule, Large Molecule), By Route Of Administration, By Therapeutic Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

无菌注射剂契约製造市场的成长和趋势：

根据Grand View Research, Inc.最新报告，预计到2030年，全球无菌注射契约製造市场规模将达319亿美元，2025年至2030年复合年增长率为12.28%。

无菌注射合约製造业的推动因素包括注射剂管道和核准的增加、生技药品和生物仿製药需求的增加、开发新疗法的研发活动投资的契约製造以及细胞和基因治疗需求的增加是推动因素。无菌注射剂的契约製造市场较为分散，多家公司拥有类似的技术力和加工能力。

具有管理高效价药物等独特能力的契约製造组织（CMO）预计将主导该行业。欧洲和美国有各种无菌注射剂 CMO，并拥有欧盟 GMP 和美国FDA 批准的设施。此外，印度和中国等新兴经济体预计在预测期内将出现良好的成长。这是由于这些国家对注射药品采购服务的需求不断增加。印度有超过20家获得欧盟GMP/美国FDA注射认证的CMO。由于製药巨头对新兴市场具有成本效益的外包服务的需求不断增长，印度的无菌注射契约製造製造业正在迅速扩张。儘管印度大多数注射剂 CMO 一直在迎合当地需求，但近年来这种转变变得明显。

COVID-19 大流行对无菌注射剂契约製造製造业产生了积极影响。这是由于 2020 年至 2021 年对 COVID-19 疫苗的需求大幅增加。市场主要参与者也正在采取合併、收购和联盟等无机策略倡议来增强其市场地位。此外，近年来，多家公司专注于进入註射剂契约製造製造业。例如，全球私人投资公司 Bridgewest Group 宣布推出专门从事无菌注射剂的新合约开发和受託製造厂商(CDMO) 设施。

无菌注射契约製造市场报告亮点

  • 按分子类型划分，大分子细分市场以 2024 年最大的销售份额 67.07% 引领市场。该行业的成长主要归因于契约製造製造商在聚合物治疗药物开发方面的投资增加、注射生技药品管道的扩大以及美国FDA 对生物相似药的核准大幅增加。
  • 从治疗应用来看，肿瘤领域以2024年最大的销售份额28.17%引领市场。癌症患者数量的增加、研发投资的增加以及对癌症药物和生技药品的需求不断增长是推动该行业增长的因素之一。
  • 从给药途径来看，静脉注射(IV) 细分市场在 2024 年以 30.35% 的最大销售份额引领市场。多个医疗保健系统正在转向个人化医疗，推动了对客製化静脉治疗的需求。
  • 以最终用途划分，製药公司细分市场以 2024 年最高收益占有率43.48% 领先市场。为了专注于研发等核心能力，製药公司越来越多地将药物开发和製造业务委託给契约製造组织（CMO）。
  • 北美无菌注射契约製造市场将在 2024 年占据主导地位，销售份额将达到 42.86%。该地区的成长得益于先进的医疗基础设施、研发投资的增加、技术的发展以及大公司的存在等因素。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 无菌注射契约製造市场的变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 无菌注射契约製造市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第 4 章：无菌注射契约製造市场：分子类型估计与趋势分析

  • 细分仪表板
  • 全球无菌注射剂契约製造市场分子型波动分析
  • 2018-2030年全球无菌注射契约製造市场规模及趋势分析（依分子类型）
  • 低分子
  • 大分子

第五章 无菌注射剂契约製造市场：治疗应用的估计和趋势分析

  • 细分仪表板
  • 全球无菌注射契约製造市场治疗应用波动分析
  • 2018-2030年全球无菌注射合约契约製造市场规模与趋势分析（依治疗应用）
  • 癌症
  • 糖尿病
  • 心血管疾病
  • 中枢神经系统疾病
  • 感染疾病
  • 肌肉骨骼
  • 抗病毒药
  • 其他的

第六章 无菌注射契约製造市场：给药途径预估及趋势分析

  • 细分仪表板
  • 全球无菌注射剂契约製造市场给药途径变化分析
  • 2018-2030年全球无菌注射合约契约製造市场规模与趋势分析（依管理途径）
  • 皮下注射（SC）
  • 静脉注射 (IV)
  • 肌肉注射 (IM)
  • 其他的

第七章无菌注射契约製造市场：最终用途估计和趋势分析

  • 细分仪表板
  • 全球无菌注射剂契约製造市场的最终用途变化分析
  • 2018-2030 年全球无菌注射契约製造市场规模和趋势分析（按最终用途）
  • 製药公司
  • 生物製药公司
  • 其他的

第 8 章无菌注射契约製造市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 挪威
    • 瑞典
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 公司/竞争对手分类
  • 策略规划
  • 2024 年企业市场分析
  • 公司简介
    • Baxter
    • Catalent, Inc.
    • Vetter Pharma
    • Recipharm AB
    • Aenova Group
    • Fresenius Kabi AG
    • Unither Pharmaceuticals
    • FAMAR Health Care Services
    • Cipla Inc.
    • NextPharma Technologies
Product Code: GVR-4-68040-097-0

Sterile Injectable Contract Manufacturing Market Growth & Trends:

The global sterile injectable contract manufacturing market size is expected to reach USD 31.9 billion by 2030, registering a CAGR of 12.28% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing pipeline and approvals of injectables, growing demand for biologics and biosimilars, rise in investment in research & development activities for the development of novel therapeutics, and increasing demand for cell & gene therapies are the key factors driving the growth of sterile injectable contract manufacturing industry. The market for sterile injectable contract manufacturing is fragmented, with several players having similar technological and processing capabilities.

Contract Manufacturing Organizations (CMOs) with unique capabilities, such as the management of high-potency drugs, are anticipated to dominate the industry. In Europe and the U.S., there are various sterile injectable CMOs with EU GMP and U.S. FDA-approved facilities. Moreover, developing economies such as India and China are anticipated to witness lucrative growth across the forecast period. This is attributable to the increasing demand for injectable sourcing services across these countries. India has over 20 CMOs with EU GMP/U.S. FDA injectable certifications. The Indian sterile injectable contract manufacturing industry is rapidly expanding due to rising demand for outsourcing services from the pharmaceutical giants to emerging markets for cost-effectiveness. Most Indian injectable CMOs have been catering to local demand, but the transition has been evident over the past few years.

The COVID-19 pandemic positively impacted the sterile injectable contract manufacturing industry. This was because of the huge surge in demand for COVID-19 vaccines from 2020 to 2021, as these vaccines are a major part of the injectables industry. In addition, major players in the market are adopting inorganic strategic initiatives such as mergers, acquisitions, and partnerships to enhance their market positions. Furthermore, for the past few years, several companies have focused on penetrating the injectable contract manufacturing industry. For instance, Bridgewest Group, a global private investment firm, announced the launch of a new contract development and manufacturing organization (CDMO) facility focused on sterile injectable drug products.

Sterile Injectable Contract Manufacturing Market Report Highlights:

  • Based on molecule type, the large molecule segment led the market with the largest revenue share of 67.07% in 2024. The growth of the segment is mainly due to rising investments by contract manufacturers in developing large molecule-based therapeutics, an expanding pipeline of biologics injectables, and a notable increase in U.S. FDA approvals for biosimilars.
  • Based on therapeutic application, the cancer segment led the market with the largest revenue share of 28.17% in 2024. The increasing number of cancer cases, rising R&D investments, and growing requirements for oncology drugs & biologics are some of the factors driving the segment growth.
  • Based on route of administration, the intravenous (IV) segment led the market with the largest revenue share of 30.35% in 2024. Several healthcare systems are shifting toward personalized medicine, which is boosting the demand for tailored intravenous therapies.
  • Based on end use, the pharmaceutical companies segment led the market with the largest revenue share of 43.48% in 2024. Pharmaceutical companies are increasingly outsourcing their drug development and manufacturing operations to Contract Manufacturing Organizations (CMOs) to focus on their core competencies, such as R&D.
  • North America sterile injectable contract manufacturing market dominated with the revenue share of 42.86% in 2024. The growth in the region is attributed to the factors such as to the region's advanced healthcare infrastructure, increasing R&D investment, technological developments, and the presence of major players.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Molecule Type Segment
    • 1.2.2. Molecule Therapeutic Application Segment
    • 1.2.3. Route of Administration Segment
    • 1.2.4. End Use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Sterile Injectable Contract Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Pipeline and Approvals of Injectables
      • 3.2.1.2. Growing Demand for Biologics and Biosimilars Significantly Supported Market Growth
      • 3.2.1.3. Rise in Investment Across Research & Development Activities for the Development of Novel Therapeutics
      • 3.2.1.4. Increasing Demand for Cell & Gene Therapies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Low Barriers to Market Penetration Have Resulted in Pricing Pressure
      • 3.2.2.2. Challenges Related to Quality Control
  • 3.3. Sterile Injectable Contract Manufacturing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Sterile Injectable Contract Manufacturing Market: Molecule Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Sterile Injectable Contract Manufacturing Market Molecule Type Movement Analysis
  • 4.3. Global Sterile Injectable Contract Manufacturing Market Size & Trend Analysis, by Molecule Type, 2018 to 2030 (USD Million)
  • 4.4. Small Molecule
    • 4.4.1. Small molecule market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Large Molecule
    • 4.5.1. Large molecule market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Sterile Injectable Contract Manufacturing Market: Therapeutic Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Sterile Injectable Contract Manufacturing Market Therapeutic Application Movement Analysis
  • 5.3. Global Sterile Injectable Contract Manufacturing Market Size & Trend Analysis, by Therapeutic Application, 2018 to 2030 (USD Million)
  • 5.4. Cancer
    • 5.4.1. Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Diabetes
    • 5.5.1. Diabetes market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Cardiovascular Diseases
    • 5.6.1. Cardiovascular diseases market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Central Nervous Systems Diseases
    • 5.7.1. Central nervous systems diseases market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.8. Infectious Disorders
    • 5.8.1. Infectious disorders market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.9. Musculoskeletal
    • 5.9.1. Musculoskeletal market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.10. Anti-Viral
    • 5.10.1. Anti-Viral market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.11. Others
    • 5.11.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Sterile Injectable Contract Manufacturing Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Sterile Injectable Contract Manufacturing Market Route of Administration Movement Analysis
  • 6.3. Global Sterile Injectable Contract Manufacturing Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Subcutaneous (SC)
    • 6.4.1. Subcutaneous (SC) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Intravenous (IV)
    • 6.5.1. Intravenous (IV) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Intramuscular (IM)
    • 6.6.1. Intramuscular (IM) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Sterile Injectable Contract Manufacturing Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Sterile Injectable Contract Manufacturing Market End Use Movement Analysis
  • 7.3. Global Sterile Injectable Contract Manufacturing Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 7.4. Pharmaceutical Companies
    • 7.4.1. Pharmaceutical companies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5. Biopharmaceutical Companies
    • 7.5.1. Biopharmaceutical companies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Sterile Injectable Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Competitive scenario
      • 8.4.2.3. Regulatory Landscape
      • 8.4.2.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Competitive scenario
      • 8.4.3.3. Regulatory Landscape
      • 8.4.3.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Competitive scenario
      • 8.4.4.3. Regulatory Landscape
      • 8.4.4.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Competitive scenario
      • 8.5.2.3. Regulatory Landscape
      • 8.5.2.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Competitive scenario
      • 8.5.3.3. Regulatory Landscape
      • 8.5.3.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Competitive scenario
      • 8.5.4.3. Regulatory Landscape
      • 8.5.4.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Competitive scenario
      • 8.5.5.3. Regulatory Landscape
      • 8.5.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Competitive scenario
      • 8.5.6.3. Regulatory Landscape
      • 8.5.6.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Competitive scenario
      • 8.5.7.3. Regulatory Landscape
      • 8.5.7.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.8. Norway
      • 8.5.8.1. Key country dynamics
      • 8.5.8.2. Competitive scenario
      • 8.5.8.3. Regulatory Landscape
      • 8.5.8.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.9. Sweden
      • 8.5.9.1. Key country dynamics
      • 8.5.9.2. Competitive scenario
      • 8.5.9.3. Regulatory Landscape
      • 8.5.9.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Competitive scenario
      • 8.6.2.3. Regulatory Landscape
      • 8.6.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Competitive scenario
      • 8.6.3.3. Regulatory Landscape
      • 8.6.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Competitive scenario
      • 8.6.4.3. Regulatory Landscape
      • 8.6.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Competitive scenario
      • 8.6.5.3. Regulatory Landscape
      • 8.6.5.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Competitive scenario
      • 8.6.6.3. Regulatory Landscape
      • 8.6.6.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Competitive scenario
      • 8.6.7.3. Regulatory Landscape
      • 8.6.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Competitive scenario
      • 8.7.2.3. Regulatory Landscape
      • 8.7.2.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Competitive scenario
      • 8.7.3.3. Regulatory Landscape
      • 8.7.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Competitive scenario
      • 8.8.2.3. Regulatory Landscape
      • 8.8.2.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Competitive scenario
      • 8.8.3.3. Regulatory Landscape
      • 8.8.3.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key country dynamics
      • 8.8.4.2. Competitive scenario
      • 8.8.4.3. Regulatory Landscape
      • 8.8.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key country dynamics
      • 8.8.5.2. Competitive scenario
      • 8.8.5.3. Regulatory Landscape
      • 8.8.5.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2024
  • 9.4. Company Profiles/Listing
    • 9.4.1. Baxter
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Catalent, Inc.
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Vetter Pharma
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Recipharm AB
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Aenova Group
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Fresenius Kabi AG
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Unither Pharmaceuticals
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. FAMAR Health Care Services
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Cipla Inc.
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. NextPharma Technologies
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 4. Global Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 5. Global Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 6. Global Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 7. Global Sterile Injectable Contract Manufacturing, by region, 2018 - 2030 (USD Million)
  • Table 8. North America Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 9. North America Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 10. North America Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 11. North America Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 12. U.S. Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 13. U.S. Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 14. U.S. Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 15. Canada Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 16. Canada Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 17. Canada Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 18. Canada Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 19. Mexico Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 20. Mexico Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 21. Mexico Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 22. Mexico Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 23. Europe Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 24. Europe Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 25. Europe Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 26. Europe Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 27. Germany Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 28. Germany Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 29. Germany Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 30. Germany Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 31. UK Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 32. UK Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 33. UK Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 34. UK Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 35. France Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 36. France Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 37. France Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 38. France Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 39. Italy Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 40. Italy Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 41. Italy Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 42. Italy Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 43. Spain Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 44. Spain Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 45. Spain Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 46. Spain Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 47. Denmark Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 48. Denmark Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 49. Denmark Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 50. Denmark Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 51. Norway Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 52. Norway Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 53. Norway Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 54. Norway Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 55. Sweden Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 56. Sweden Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 57. Sweden Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 58. Sweden Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 59. Asia Pacific Sterile Injectable Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 60. Asia Pacific Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 61. Asia Pacific Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 62. Asia Pacific Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 63. Asia Pacific Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 64. China Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 65. China Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 66. China Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 67. China Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 68. Japan Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 69. Japan Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 70. Japan Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 71. Japan Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 72. India Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 73. India Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 74. India Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 75. India Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 76. South Korea Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 77. South Korea Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 78. South Korea Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 79. South Korea Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 80. Australia Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 81. Australia Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 82. Australia Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 83. Australia Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 84. Thailand Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 85. Thailand Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 86. Thailand Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 87. Thailand Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 88. Latin America Sterile Injectable Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 89. Latin America Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 90. Latin America Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 91. Latin America Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 92. Latin America Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 93. Brazil Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 94. Brazil Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 95. Brazil Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 96. Brazil Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 97. Argentina Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 98. Argentina Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 99. Argentina Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 100. Argentina Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 101. Middle East & Africa Sterile Injectable Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 102. Middle East & Africa Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 103. Middle East & Africa Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 104. Middle East & Africa Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 105. Middle East & Africa Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 106. South Africa Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 107. South Africa Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 108. South Africa Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 109. South Africa Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 110. Saudi Arabia Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 111. Saudi Arabia Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 112. Saudi Arabia Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 113. Saudi Arabia Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 114. UAE Sterile Injectable Contract Manufacturing, by Therapeutic Application, 2018 - 2030 (USD Million)
  • Table 115. UAE Sterile Injectable Contract Manufacturing, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 116. UAE Sterile Injectable Contract Manufacturing, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 117. UAE Sterile Injectable Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Sterile Injectable Contract Manufacturing Market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot 1
  • Fig. 14 Segment snapshot 2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Sterile Injectable Contract Manufacturing Market: Molecule Type outlook key takeaways
  • Fig. 20 Sterile Injectable Contract Manufacturing Market: Molecule Type movement analysis
  • Fig. 21 Small Molecule estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Large Molecule market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Sterile Injectable Contract Manufacturing Market: Therapeutic Application outlook key takeaways
  • Fig. 24 Sterile Injectable Contract Manufacturing Market: Therapeutic Application movement analysis
  • Fig. 25 Cancer estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Diabetes estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Cardiovascular Diseases estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Central Nervous Systems Diseases estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Infectious Disorders estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Musculoskeletal estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Anti-Viral estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Others estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Sterile Injectable Contract Manufacturing Market: Route of Administration outlook key takeaways
  • Fig. 34 Sterile Injectable Contract Manufacturing Market: Route of Administration movement analysis
  • Fig. 35 Subcutaneous (SC) estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Intravenous (IV) estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Intramuscular (IM) estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Others estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Sterile Injectable Contract Manufacturing Market: End Use outlook key takeaways
  • Fig. 40 Sterile Injectable Contract Manufacturing Market: End Use movement analysis
  • Fig. 41 Pharmaceutical Companies estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Biopharmaceutical Companies estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Others estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Regional marketplace outlook, 2024 & 2030 (USD Million)
  • Fig. 45 Regional marketplace: Key takeaways
  • Fig. 46 North America Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 US Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Canada Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Mexico Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Europe Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 UK Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Germany Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 France Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Spain Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Italy Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Denmark Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Norway Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Sweden Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Asia Pacific Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Japan Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 China Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 India Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Australia Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Korea Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Thailand Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Latin America Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 Brazil Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Argentina Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 MEA Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 South Africa Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Saudi Arabia Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 UAE Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Key country dynamics
  • Fig. 97 Kuwait Sterile Injectable Contract Manufacturing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Market participant categorization
  • Fig. 99 Sterile Injectable Contract Manufacturing Market Position Analysis, 2024
  • Fig. 100 Strategic framework